Dr. Dale Bredesen was joined by Co-Founder and Chief Science Officer, and Medical Director of IntellxxDNA, Dr. Sharon Hausman-Cohen, for the webinar “The Role of Advanced Genomics in Improving Outcomes in Cognitive Decline.”

Dr. Hausman-Cohen is one of the co-authors along with Dr. Bredesen for our recent Precision Medicine Trial, which used IntellxxDNA’s Clinical Decision Support Tool, a proprietary genomic research and intelligence platform used to identify contributing risk factors for cognitive decline.

Dr. Hausman-Cohen and Dr. Bredesen discussed how best to improve treatment outcomes using this genomics tool paired with ReCODE 2.0 to create a targeted, individualized, and precise approach.

Watch here:

Share This: